Olmesartan medoxomil single drug and application of olmesartan medoxomil and sorafenib combined therapy in prevention / treatment of diabetes mellitus

Through the combination of olmesartanate and sorafenib, block inflammation and inhibit Th1 cell differentiation, successfully prevent and treat type 1 diabetes, solving the problem that existing treatment methods cannot protect pancreatic islet β cells, and providing oral drug treatment The plan avoids the inconvenience of injection therapy.

CN118924745APending Publication Date: 2024-11-12THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411209220.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Treatment methods for type 1 diabetes have failed to essentially improve the immune environment, and islet beta cells are still under immune attack, and existing drugs cannot effectively prevent or reverse the severely damaged islet beta cell function.

Method used

Olmesartan olefin or its derivatives are used as selective angiotensin II receptor antagonist, combined with sorafenib, protects pancreatic islet β cells by blocking inflammatory factors and inhibiting Th1 cell differentiation, providing olmesartan olefin and sorafenib Combination therapy of Rafenib.

Benefits of technology

Olmesartan methenate can prevent the occurrence of type 1 diabetes, and its use with sorafenib can reverse the hyperglycemia state and maintain blood sugar in the normal range for a long time, providing a new treatment pathway and avoiding the inconvenience of injection therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924745A_ABST
    Figure CN118924745A_ABST
Patent Text Reader

Abstract

The invention provides an application of olmesartan medoxomil or a derivative thereof in preparation of a medicine for protecting pancreatic beta cells, a medicine for protecting pancreatic beta cells to resist inflammation, a medicine for preventing and treating diabetes mellitus and a medicine for preventing and treating type 1 diabetes mellitus, and also provides an application of olmesartan medoxomil or a derivative thereof in preparation of a medicine for preventing and treating type 1 diabetes mellitus. The invention also provides application of the olmesartan medoxomil and sorafenib combined therapy in treatment of type 1 diabetes mellitus. The olmesartan medoxomil is used for preventive treatment of the type 1 diabetes mellitus, and the olmesartan medoxomil and sorafenib combined therapy is used for treatment of the type 1 diabetes mellitus, so that a new treatment way is provided for the majority of patients, and more choices are provided for clinicians and the patients. For patients with type 1 diabetes, the preventive treatment of olmesartan medoxomil and the combination therapy of olmesartan medoxomil and sorafenib can provide oral drug therapy for the patients, and the trouble of CD3 monoclonal antibody injection even daily insulin injection is avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a new application of Olmesartan Medoxomil, in particular to the application of Olmesartan Medoxomil alone and in combination with Sorafenib in the prevention / treatment of type 1 diabetes. Background Art

[0002] Type 1 diabetes mellitus (T1DM), also known as autoimmune diabetes, is a typical autoimmune disease caused by the combined effects of genetic and environmental factors, which causes pancreatic β cells to be damaged by autoimmune attacks. It is characterized by insulin deficiency and hyperglycemia. T1DM is one of the common chronic diseases in children and adolescents, and its incidence is on the rise worldwide. Although China is one of the countries with a low incidence of T1DM in the world, due to its large population base, the number of children and adolescents with T1DM ranks fourth in the world, and the disease burden is becoming increasingly heavy. At present, the main treatments for T1DM are insulin and pancreatic β cell / stem cell transplantation. Although these methods can relieve symptoms, none of them fundamentally improve the immune environment, and pancreatic β cells still die due to immune attacks. To this day, T1DM is still incurable, and the development of new drugs based on the pathogenesis is urgent.

[0003] Pancreatic β-cell failure caused by autoimmune activation dominated by immune cells is a key mechanism for the onset of T1DM. Immunotherapy has always been highly anticipated. Studies have shown that the destruction of pancreatic β-cells during the onset of T1DM is mainly mediated by autoreactive T cells, so targeting autoreactive T cells brings new hope to the treatment of T1DM. CD3 monoclonal antibody (telizumab) is the first immunotherapy approved by the U.S. Food and Drug Administration (FDA) to delay the onset of T1DM. Its Phase II clinical data showed that 2 weeks of administration significantly delayed the onset of T1DM in high-risk children and adults, and the median time of onset was delayed by at least 2 years. This study shows that immunotherapy targeting T cells is an effective means to delay T1DM.

[0004] The activation of Th1 cells plays a key role in the pathogenesis of T1DM. Therefore, Th1 cells are an important target for immunotherapy of T1DM. In the early stage, we used an in vitro cell model of Th1 cell differentiation induced by interleukin-12 (IL-12) to screen the FDA-approved tyrosine kinase inhibitor compound library and found an effective Th1 cell differentiation inhibitor, sorafenib. We also confirmed that sorafenib can improve pancreatitis in non-obese diabetic (NOD) mice by inhibiting Th1 cells, thereby reversing T1DM. This study has been awarded a national invention patent (patent number: ZL 202010812329.3).

[0005] In previous studies, the efficacy of sorafenib in treating T1DM NOD mice was about 50%. For NOD mice with high initial blood sugar levels and complete destruction of pancreatic beta cells, sorafenib could not reverse the continued increase in blood sugar. This result suggests that improving the inflammatory environment in the body cannot restore the function of severely damaged pancreatic beta cells. Therefore, it is necessary to develop drugs to protect pancreatic beta cells.

[0006] Based on the pathogenesis of T1DM, a two-pronged approach of combining drugs to protect pancreatic β cells with immunotherapy to treat T1DM has important practical significance. Summary of the invention

[0007] In view of this, the present invention provides the use of olmesartan medoxomil or its derivatives in the preparation of a drug for protecting pancreatic β cells.

[0008] Furthermore, the present invention also provides the use of olmesartan medoxomil or its derivatives in the preparation of drugs for protecting pancreatic β cells from inflammation, and in the preparation of drugs for preventing and treating diabetes, especially in drugs for treating type 1 diabetes.

[0009] Furthermore, the present invention also provides the use of the combination therapy of mesartan medoxomil or its derivatives and sorafenib or its derivatives in the preparation of a drug for treating diabetes.

[0010] Olmesartan medoxomil for the preventive treatment of type 1 diabetes and the combination of olmesartan medoxomil and sorafenib for the treatment of type 1 diabetes provide new treatment options for patients and more options for clinicians and patients. For patients with type 1 diabetes, the preventive treatment of olmesartan medoxomil and the combination of olmesartan medoxomil and sorafenib can provide patients with oral medication, eliminating the trouble of tilizumab injections or even daily insulin injections.

[0011] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions: Application of olmesartan medoxomil or its derivatives in preparing medicine for protecting pancreatic beta cells.

[0012] Olmesartan Medoxomil is a prodrug that is absorbed and hydrolyzed into Olmesartan through the gastrointestinal tract. Olmesartan is a selective angiotensin II type 1 receptor (AT1) antagonist that blocks the vasoconstriction effect of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor of vascular smooth muscle. Olmesartan Medoxomil is approved by the US FDA for the treatment of hypertension. It is a first-line, long-acting antihypertensive drug widely used in clinical practice. In addition to its significant antihypertensive effect, studies have shown that it can also play an anti-inflammatory role in hypertensive patients, delay the progression of microalbuminuria and coronary atherosclerosis, indicating that Olmesartan Medoxomil has multiple protective benefits for the body. The safety of Olmesartan Medoxomil has also been fully verified in children and adolescents (6-16 years old). In addition, Olmesartan Medoxomil is not metabolized by the liver cytochrome P450 system, which improves the safety of combined medication. The molecular formula of Olmesartan medoxomil is C29H30N6O6, the molecular weight is 558.59, and the structural formula is shown in Formula I.

[0013]

[0014] Formula I.

[0015] Furthermore, some embodiments of the present invention use proinflammatory factors interleukin 1β (IL-1β), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) to treat mouse pancreatic β cell line MIN6 cells, and find that the antihypertensive drug Olmesartan medoxomil can resist inflammation and protect pancreatic β cells. The present invention confirms the use of Olmesartan medoxomil or its derivatives in the preparation of drugs for protecting pancreatic β cells from inflammation through cell experiments.

[0016] Furthermore, the present invention provides the use of Olmesartan Medoxomil or its derivatives in the preparation of drugs for preventing and treating diabetes.

[0017] In some embodiments of the present invention, Olmesartan medoxomil is used to gavage NOD mice before the onset of type 1 diabetes, monitor the changes in blood sugar in the mice, and observe the natural incidence of type 1 diabetes in the mice. The results show that Olmesartan medoxomil can prevent the occurrence of type 1 diabetes in NOD mice.

[0018] It can be seen that Olmesartan Medoxomil can be used to prevent the occurrence of type 1 diabetes. Use of Olmesartan Medoxomil or its derivatives in the preparation of drugs for preventing and treating diabetes, especially in drugs for preventing and treating type 1 diabetes.

[0019] In some embodiments, the present invention uses olmesartan medoxomil and sorafenib in combination to gavage naturally occurring type 1 diabetic NOD mice for 7 weeks, and monitors the changes in blood glucose in the mice. The results show that the combination therapy of olmesartan medoxomil and sorafenib can reverse the hyperglycemia of type 1 diabetic NOD mice and maintain blood glucose in the normal range for a long time after drug withdrawal.

[0020] Conclusions: Olmesartan medoxomil and sorafenib combination therapy can be used to treat type 1 diabetes.

[0021] In summary, the present invention provides the use of olmesartan medoxomil or its derivatives and sorafenib or its derivatives in combination therapy for preventing / treating diabetes.

[0022] Furthermore, the present invention also provides a use of a combination therapy of olmesartan medoxomil or its derivatives and sorafenib or its derivatives in the preparation of a drug for treating type 1 diabetes.

[0023] Wherein, the weight ratio of Olmesartan Medoxomil or its derivatives to Sorafenib or its derivatives is 2:5.

[0024] Preferably, the dosage of olmesartan medoxomil or its derivatives is 20 mg / kg, and the dosage of sorafenib or its derivatives is 50 mg / kg.

[0025] Furthermore, the medicine of the present invention also includes pharmaceutically acceptable excipients.

[0026] Furthermore, the dosage form of the drug of the present invention can be an oral preparation or an injection preparation.

[0027] Each drug dosage form can be prepared by selecting suitable acceptable excipients according to the actual needs of the dosage form, which belongs to the conventional dosage form preparation technology in the field, such as capsules, tablets, injection powders, etc.

[0028] As can be seen from the above technical scheme, the present invention provides the use of Olmesartan medoxomil or its derivatives in the preparation of drugs for protecting pancreatic β cells, drugs for protecting pancreatic β cells against inflammation, in the preparation of drugs for preventing and treating diabetes, and in the prevention and treatment of type 1 diabetes. At the same time, the present invention also provides the use of Olmesartan medoxomil and sorafenib combination therapy in the treatment of type 1 diabetes. Olmesartan medoxomil is used for the preventive treatment of type 1 diabetes and Olmesartan medoxomil and sorafenib combination therapy is used for the treatment of type 1 diabetes. It provides a new treatment approach for the majority of patients and provides more choices for clinicians and patients. For patients with type 1 diabetes, the preventive treatment of Olmesartan medoxomil and the combination therapy of Olmesartan medoxomil and sorafenib can provide patients with oral drug treatment, free from the trouble of CD3 monoclonal antibody (telizumab) injection or even daily insulin injection. Olmesartan medoxomil and sorafenib can be chemically synthesized, and the cost is lower than that of biological preparations. And it has been approved by FDA and NMPA for listing and used in clinical treatment. The side effects are fewer and milder, clinically well tolerated by patients, and the burden on patients is lighter. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for describing the embodiments or the prior art are briefly introduced below.

[0030] Figure 1 This is a result analysis diagram of the expression level of apoptosis protein - in MIN6 cells detected by flow cytometry in Example 1; Figure 2 Example 2 ELISA detection of insulin content in MIN6 cells under low sugar (2.8 mM) and high sugar (16.7 mM) conditions; Figure 3 This is a graph showing the analysis of the prevalence of type 1 diabetes in mice in Example 3; Figure 4 This is a result analysis diagram of the therapeutic effect of Olmesartan Medoxomil and Sorafenib alone on type 1 diabetic mice in Example 4; Figure 5 This is a graph analyzing the therapeutic effect of the combination of Olmesartan Medoxomil and Sorafenib on type 1 diabetic mice in Example 5. DETAILED DESCRIPTION

[0031] The present invention discloses a new application of Olmesartan Medoxomil and Sorafenib, and those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described by preferred embodiments, and relevant personnel can obviously change or appropriately change and combine the method and application described herein without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention.

[0032] Unless otherwise specified, the reagents involved in the embodiments of the present invention are all commercially available products and can be purchased through commercial channels.

[0033] Among them, interleukin-1β (IL-1β), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) were purchased from the market.

[0034] The present invention will be further described below in conjunction with the embodiments.

[0035] Example 1: Olmesartan Medoxomil protects pancreatic β cells against inflammation-induced apoptosis 1. Materials and Methods 1. Cell line: Mouse pancreatic β cell line (MIN6 cells) was selected for the experiment. The MIN6 cells of the present invention are from the ATCC cell bank in the United States.

[0036] 2. Prepare cells: MIN6 cells were cultured at 1×10 5 The cells were seeded at a density of 10 cells / well in a 24-well plate, with 1 mL of complete culture medium (DMEM+10% FBS+100 U / mL penicillin / streptomycin) added to each well, and incubated in a cell culture incubator for 2 days.

[0037] 3. Flow cytometry detection of MIN6 cell apoptosis—Annexin V staining: Preparation of solvent: DMEM and 0.1% bovine serum albumin were mixed evenly to obtain a solvent; Preparation of inflammatory factor solvent: dissolve interleukin-1β (IL-1β), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in the above solvent to prepare the inflammatory factor solvent.

[0038] The cells were divided into three groups: group A, group B, and group C. Inflammatory factor solvents were added to the complete culture medium in groups B and C, so that the final concentrations of interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) were all 20 ng / mL. Olmesartan medoxomil was added to group C to a final concentration of 1 μM. The solvent was used to make up the volumes of groups ABC to an equal volume. After 72 h of treatment, the cells were collected into 1.5 mL EP tubes, washed with pre-cooled 1× PBS, and then stained with Annexin V. The expression of Annexin V was detected by flow cytometry. Three parallel replicates were set for each treatment group, and the average value was taken and displayed in Figure 3. Figure 1 middle( Figure 1 The solvent, inflammatory factor mixture, and inflammatory factor mixture + 1 μM Olmesartan Medoxomil correspond to group A, group B, and group C, respectively, where * indicates significant differences between the groups.

[0039] from Figure 1 The results show that under the stimulation of inflammatory factors, the expression of apoptosis protein Annexin V in MIN6 cells in group B increased rapidly. The difference between group C and group B is that 1 μM olmesartan medoxomil was used. It can be seen that the expression of apoptosis protein Annexin V in MIN6 cells was significantly different from that in group B. Therefore, it can be seen that olmesartan medoxomil has the effect of resisting inflammation-induced pancreatic β-cell apoptosis.

[0040] Example 2: Olmesartan medoxomil protects the insulin secretion function of pancreatic β cells in an inflammatory environment 1. Materials and Methods 1. Cell line: Mouse pancreatic β cell line (MIN6 cells) was selected for the experiment. The MIN6 cells of the present invention are from the ATCC cell bank in the United States.

[0041] 2. Prepare cells: MIN6 cells were cultured at 1×10 5 The cells were seeded at a density of 10 cells / well in a 24-well plate, with 1 mL of complete culture medium (DMEM+10% FBS+100 U / mL penicillin / streptomycin) added to each well, and incubated in a cell culture incubator for 2 days.

[0042] 3. Divide the cells into three groups for glucose-stimulated insulin secretion experiments: Preparation of solvent: DMEM and 0.1% bovine serum albumin were mixed evenly to obtain a solvent; Preparation of inflammatory factor solvent: dissolve interleukin-1β (IL-1β), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in the above solvent to prepare the inflammatory factor solvent.

[0043] The cells were divided into three groups: group D, group E and group F. Inflammatory factor solvents were added to the complete culture medium in groups E and F, so that the final concentrations of interleukin-1β (IL-1β), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) were all 20 ng / mL. Olmesartan medoxomil was added to group F to a final concentration of 1 μM. The three groups of DEF were supplemented to equal volumes with solvents. After 24 hours of treatment, the culture medium was discarded and the adherent cells were washed twice with Krebs-Ringer bicarbonate buffer (KRB). The cells were starved for 1 hour using KRB solution containing 2.8 mmol / L low-concentration glucose and 0.3% BSA. After starvation, the three groups of MIN6 cells were stimulated with 2.8 mmol / L low glucose and 16.7 mmol / L high glucose for 1 hour, respectively. The cell culture supernatant was collected and the insulin level was detected by ELISA, as shown in Figure 2 As shown ( Figure 2 The solvent, the inflammatory factor combination, and the inflammatory factor combination + 1 μM Olmesartan Medoxomil correspond to group D, group E, and group F, respectively). Each treatment group was repeated three times and the average value was taken.

[0044] from Figure 2 It can be seen that Olmesartan medoxomil can maintain the insulin secretion function of pancreatic β cells in an inflammatory environment.

[0045] Example 3: Olmesartan Medoxomil can prevent the occurrence of type 1 diabetes in NOD mice 1. Mice: The classic mouse model for studying type 1 diabetes, namely the spontaneous type 1 diabetes mouse model, NOD mice, was selected. Since the incidence of spontaneous type 1 diabetes in female NOD mice is much higher than that in male NOD mice, female NOD mice were used for the experiment. The female NOD mice of the present invention were purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0046] 2. Preparation: Use sterile water as the solvent for Olmesartan Medoxomil: Before preparation, sterilize the drinking water for mice under high pressure, dissolve Olmesartan Medoxomil tablets in sterile water on a clean bench and store at 4° to obtain Olmesartan Medoxomil solution.

[0047] 3. Administration: The present invention adopts the form of gavage to administer medicine to mice, and the concentration of Olmesartan Medoxomil is 20 mg / kg body weight.

[0048] 4. Measure blood sugar to confirm type 1 diabetes: Cut off about 1mm of the mouse tail tip, wipe off the first drop of blood with gauze, and when the second drop of blood flows out, absorb and read the blood sugar test strip. If two consecutive blood sugar readings are greater than 250mg / dL, it can be diagnosed as type 1 diabetes.

[0049] 5. Observe the preventive effect of Olmesartan Medoxomil on spontaneous type 1 diabetes in NOD mice: The mice were divided into two groups, one group was gavaged with Olmesartan Medoxomil, and the other group was gavaged with sterile water. When the mice participating in the experiment were not sick, they were gavaged once a day from 8 weeks of age for 12 consecutive weeks. The natural incidence of type 1 diabetes in mice was observed and counted, which is listed in Table 1. Figure 3 .

[0050] Table 1 Disease rate of NOD mice

[0051] There were 5 mice in the solvent (sterile water) group and 6 mice in the olmesartan medoxomil group. Survival curves of the two groups of mice were analyzed at 30 weeks: * represents P The value was <0.05. It was observed that at 17 weeks of age, the prevalence of type 1 diabetes in the olmesartan medoxomil group was 16.7%, while that in the sterile water group was 80%. After stopping the administration, the preventive effect of the olmesartan medoxomil group on type 1 diabetes still existed and lasted until 30 weeks; this suggests that olmesartan medoxomil has a preventive effect on type 1 diabetes.

[0052] Example 4 Olmesartan Medoxomil and Sorafenib Therapeutic Effects of Sorafenib Alone on Type 1 Diabetic Mice 1. Mice: The classic mouse model for studying type 1 diabetes, namely the spontaneous type 1 diabetes mouse model, NOD mice, was selected. Since the incidence of spontaneous type 1 diabetes in female NOD mice is much higher than that in male NOD mice, female NOD mice were used for the experiment. The female NOD mice of the present invention were purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0053] 2. Preparation: Use sterile water as the solvent for Olmesartan Medoxomil: sterilize the drinking water for mice under high pressure, dissolve Olmesartan Medoxomil tablets in sterile water on a clean bench and store at 4° to obtain Olmesartan Medoxomil solution.

[0054] Use 1% carboxymethyl cellulose (CMC) as the solvent for sorafenib: sterilize 1% CMC under high pressure before dispensing, grind the sorafenib tablets into powder on an ultra-clean workbench, and then weigh an appropriate amount of sorafenib powder, suspend it evenly in the solvent and store it at 4° to obtain sorafenib suspension.

[0055] 3. Administration: The present invention adopts the form of gavage to administer drugs to mice, the concentration of olmesartan medoxomil is 20 mg / kg body weight, and the concentration of sorafenib is 50 mg / kg body weight.

[0056] 4. Measure blood sugar to diagnose type 1 diabetes: cut off about 1mm of the mouse tail tip, wipe off the first drop of blood with gauze, and when the second drop of blood flows out, absorb and read the blood sugar test strip. If two consecutive blood sugar readings are >250mg / dL, type 1 diabetes can be diagnosed.

[0057] 5. Observe the therapeutic effects of Olmesartan Medoxomil and Sorafenib alone on type 1 diabetic mice NOD mice were divided into three groups: one group was a solvent group (sterile water + CMC), one group was an olmesartan medoxomil group, and one group was an sorafenib group. From the time the mice were diagnosed with type 1 diabetes, the mice were gavaged once a day for 3 consecutive weeks. Blood sugar was monitored every week. The blood sugar values ​​are listed in Table 2, and the blood sugar values ​​after 3 weeks are compared in Table 3. The effect comparison is shown in Table 3. Figure 4 .

[0058] Table 2 Blood glucose values ​​of NOD mice after disease onset with single medication

[0059] Table 3 Blood glucose levels of NOD mice after 3 weeks of medication

[0060] There were 6 mice in the solvent group (sterile water + CMC), 8 mice in the olmesartan medoxomil group, and 6 mice in the sorafenib group. Blood glucose statistical analysis was performed on the olmesartan medoxomil group vs the solvent group and the sorafenib group vs the solvent group 3 weeks after the onset of the disease. Statistical analysis was performed using independent sample t-test: NS (No significance) represents no statistical difference, * represents P Value < 0.05.

[0061] The results show that Figure 4 a shows the blood glucose changes of type 1 diabetic mice given solvent (sterile water + CMC) by gavage; b shows the blood glucose changes of type 1 diabetic mice given olmesartan by gavage; c shows the blood glucose changes of type 1 diabetic mice given sorafenib by gavage; d shows the statistical analysis results of blood glucose of three groups of type 1 diabetic mice given gavage; there was no difference in blood glucose between the mice in the olmesartan medoxomil monotherapy group and the sterile water + CMC group, while the blood glucose of the mice in the sorafenib monotherapy group was lower than that in the sterile water + CMC group, which suggests that olmesartan medoxomil monotherapy cannot treat type 1 diabetes in NOD mice, while sorafenib has a certain therapeutic effect on type 1 diabetes.

[0062] Example 5 Olmesartan Medoxomil combined with sorafenib in the treatment of type 1 diabetes in NOD mice 1. Mice: The classic mouse model for studying type 1 diabetes, namely the spontaneous type 1 diabetes mouse model, NOD mice, was selected. Since the incidence of spontaneous type 1 diabetes in female NOD mice is much higher than that in male NOD mice, female NOD mice were used for the experiment. The female NOD mice of the present invention were purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0063] 2. Preparation: Use sterile water as the solvent for Olmesartan Medoxomil: sterilize the drinking water for mice under high pressure, dissolve Olmesartan Medoxomil tablets in sterile water on a clean bench and store at 4° to obtain Olmesartan Medoxomil solution.

[0064] Use 1% carboxymethyl cellulose (CMC) as the solvent for sorafenib: sterilize 1% CMC under high pressure before dispensing, grind the sorafenib tablets into powder on an ultra-clean workbench, and then weigh an appropriate amount of sorafenib powder, suspend it evenly in the solvent and store it at 4° to obtain sorafenib suspension.

[0065] 3. Administration: The present invention adopts the form of gavage to administer drugs to mice, the concentration of olmesartan medoxomil is 20 mg / kg body weight, and the concentration of sorafenib is 50 mg / kg body weight.

[0066] 4. Measure blood sugar to diagnose type 1 diabetes: cut off about 1mm of the mouse tail tip, wipe off the first drop of blood with gauze, and when the second drop of blood flows out, absorb and read the blood sugar test strip. If two consecutive blood sugar readings are >250mg / dL, type 1 diabetes can be diagnosed.

[0067] 5. Observe the synergistic effect of olmesartan medoxomil and sorafenib combined in the treatment of type 1 diabetic mice The NOD mice were divided into two groups, one group was gavaged with Olmesartan Medoxomil + Sorafenib, and the other group was gavaged with sterile water + CMC. From the time the mice were diagnosed with type 1 diabetes, the mice were gavaged once a day for 7 consecutive weeks, and the blood sugar was monitored every week. The blood sugar values ​​are listed in Table 4. Figure 5 .

[0068] Table 4 Blood glucose levels of NOD mice after combined medication

[0069] There were 3 mice in the solvent group (sterile water + CMC) and 3 mice in the olmesartan medoxomil + sorafenib group. Blood glucose was statistically analyzed in the two groups of mice at 16 weeks using independent sample t-test: *** represents P Value < 0.001.

[0070] The results are shown in Figure 5In the figure, Figure a shows the blood glucose changes of mice with type 1 diabetes mellitus gavaged with solvent (sterile water + CMC) group; Figure b shows the blood glucose changes of mice with type 1 diabetes mellitus gavaged with Olmesartan Medoxomil + Sorafenib group; Figure c shows the blood glucose statistical analysis results of the two groups of mice with type 1 diabetes gavaged with Olmesartan Medoxomil. The results of Example 4 show that the blood glucose of mice in the Olmesartan Medoxomil monotherapy group is no different from that in the sterile water + CMC group, and the blood glucose of mice in the sorafenib monotherapy group is lower than that in the sterile water + CMC group. The results of Example 5 show that the blood glucose of mice in the Olmesartan Medoxomil + Sorafenib group is significantly lower than that in the sterile water + CMC group, and the therapeutic effect of the Olmesartan Medoxomil + Sorafenib group on type 1 diabetes still exists after stopping the gavage, and lasts for 16 weeks.

[0071] It can be seen that the efficacy of sorafenib alone in treating type 1 diabetes is not high, which is lower than the efficacy of olmesartan medoxomil and sorafenib combined for 3 weeks in Example 5. In addition, after 3 weeks, the therapeutic effect of sorafenib alone began to fail, and the treatment persistence was lower than the therapeutic effect of olmesartan medoxomil and sorafenib combined. These results show that the combined therapy of olmesartan medoxomil and sorafenib has a significant improvement on the effect of sorafenib alone in the treatment of type 1 diabetes in NOD mice.

[0072] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Use of Olmesartan Medoxomil or its derivatives in the preparation of drugs for protecting pancreatic β cells.

2. Use of Olmesartan Medoxomil or its derivatives in the preparation of drugs for protecting pancreatic β cells against inflammation.

3. Use of Olmesartan Medoxomil or its derivatives in the preparation of drugs for preventing and treating diabetes.

4. Use of Olmesartan Medoxomil or its derivatives in the preparation of drugs for preventing and treating type 1 diabetes.

5. Use of the combination therapy of Olmesartan Medoxomil or its derivatives and Sorafenib or its derivatives in the preparation of drugs for treating diabetes.

6. Use of a combination therapy of olmesartan medoxomil or its derivatives and sorafenib or its derivatives in the preparation of a drug for treating type 1 diabetes.

7. The drug according to claim 5 or 6, characterized in that: The weight ratio of Olmesartan Medoxomil or its derivatives to Sorafenib or its derivatives is 2:

5.

8. The drug according to claim 7, characterized in that: The dosage of Olmesartan Medoxomil or its derivatives is 20 mg / kg, and the dosage of Sorafenib or its derivatives is 50 mg / kg.

9. The use according to any one of claims 1 to 8, characterized in that: The drug also includes pharmaceutically acceptable excipients.

10. The use according to any one of claims 1 to 8, characterized in that: The dosage form of the drug is an oral preparation or an injection preparation.

Citation Information

Cited By

  • Use of olmesartan medoxomil monotherapy and combination therapy thereof with sorafenib in prevention / treatment of diabetes

    WO2026046429A1